A cellular hierarchy framework for understanding heterogeneity and predicting drug response in acute myeloid leukemiaAndy G.X. Zeng, John E. Dick, Michelle Chan‐Seng‐Yue et al.|Nature Medicine|2022Cited by 338
Lenalidomide promotes the development of <i>TP53</i>-mutated therapy-related myeloid neoplasmsAdam S. Sperling, Koichi Takahashi, Veronica Guerra et al.|Blood|2022Cited by 138
Crbn I391V is sufficient to confer in vivo sensitivity to thalidomide and its derivatives in miceEmma C. Fink, Benjamin L. Ebert, Marie McConkey et al.|Blood|2018Cited by 126